Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the ...

Somerville, Mass-based Mass General Brigham has rolled out ambient documentation using generative AI to help draft clinical ...

The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...

The FDA has approved an investigational device exemption (IDE) application for the start of a pilot study evaluating the Alpha diffusing alpha-emitters radiation therapy (DaRT) technology in patients ...

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria ...

Knowing how much nitrogen to apply is crucial to any farming operation and researchers in Minnesota are determining the ...

Singapore telco trials cloud-based radio access network, unlocking new enterprise services and laying the groundwork for advanced 5G and 6G capabilities ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Drug developers can now leverage large language models to draft regulatory documents, which they hope will shorten the time to market.

"We are hoping that there won’t be an interlocutors application brought in that would frustrate the progression of the trial to finality," said Mhaga. Discover the Truth Step into a world where the ...

"And a delay here? Delay is the enemy of justice." The latest holdup stems from a pair of defence applications filed Wednesday morning, in which lawyer Mark Gruchy is asking for more information ...